The path through drug development is marked by detours, roadblocks and very few shortcuts. At times you may feel that you’re the only person keeping your molecule on its critical path. Unexpected delays can lead to missed milestones, rework and delayed timelines—all setbacks that no one wants to explain to their investors.
Quick to Care™ delivers a streamlined drug development program, designed specifically for new and emerging companies. This program combines your drug substance and drug product development, clinical manufacturing, forecasting, demand planning and clinical trial supply execution into a single solution to accelerate your discovery through clinical development.
By working with Patheon CDMO services within Thermo Fisher Scientific, you position your molecule for greater therapeutic and financial success because it has been formulated with scale-up in mind.
Our clients have reduced their drug development timelines by an average of 14 weeks, which translates to a total net gain of approximately $44MM, as reported by the Tufts Center for the Study of Drug Development.
These savings are driven by our experience guiding new and emerging clients through each phase of drug development. More than 75% of our drug development projects are with new and emerging clients—564 projects in 2016 alone, including 221 Phase I projects, 109 Phase II projects and 234 Phase III projects. We are the leading partner for outsourced NDA launches, with 112 NDA approvals in the last decade—that’s more than twice the number from the next ranking CDMO.
Whether your goal is out-licensing at Phase IIb or taking your molecule to full commercialization, your team at Patheon is with you every step of the way. Your Quick to Care™ program is an extension of your team, providing unified program management, scientific and technical insight, and reduction of redundancies. Download our Quick to Care™ Information Sheet.
Contact us to find out if Patheon Quick to Care™ is the right fit for your next project.